References

• 1998Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action1,015 cited
• 1998The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans577 cited
• 1998Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers448 cited
• 1997Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis444 cited
• 1986Subjective Reports of the Effects of MDMA in a Clinical Setting413 cited
• 1999Serotonin and Hallucinogens371 cited
• 1999Cardiovascular and Neuroendocrine Effects and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Humans362 cited
• 19995-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride304 cited
• 1974The Botany and Chemistry of Hallucinogens255 cited
• 2000Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram248 cited
• 2000Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans245 cited
• 1999Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG219 cited
• 1990